Experience

Davis Polk advised the underwriters in connection with the $200 million initial public offering of 20,000,000 units of Decarbonization Plus Acquisition Corporation. Each unit consists…

Davis Polk advised the joint book-running managers in connection with the $97.75 million initial public offering of 9,775,000 units of Turmeric Acquisition Corp., which includes 1,275…

Davis Polk advised the underwriters in connection with the $575 million initial public offering of 57,500,000 units of Vy Global Growth, which includes 7,500,000 units from the full…

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised Max Stock Ltd., as the issuer and Moose Holdco Ltd., Uri Max Ltd. and Oria & Iris Ltd. LP, as the selling shareholders on Max Stock’s initial public offering and…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Wix.com Ltd. of $575 million aggregate principal amount of its 0%…

Davis Polk advised the joint book running managers in connection with the $377.3 million initial public offering of 17,968,750 shares of common stock of Oak Street Health, Inc., which…

Davis Polk advised Amdocs Limited on its $650 million SEC-registered debt offering of 2.583% notes due 2030.   Amdocs Limited is a leading software and services provider to…

Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary…